Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 6—December 2001
Perspective

Developing New Smallpox Vaccines

Steven R. RosenthalComments to Author , Michael Merchlinsky, Cynthia Kleppinger, and Karen L. Goldenthal
Author affiliations: Food and Drug Administration, Rockville, Maryland, USA

Main Article

Table A3

U.S. Code of Federal Regulations (CFR) and US Pharmacopeia (USP) Standards Applicable to Vaccines

Issuance Subject
21 CFR 50 Protection of Human Subjects
21 CFR 56 Institutional Review Boards
21 CFR 58 Good Laboratory Practices
21 CFR 210, 211 Good Manufacturing Practices
21 CFR 312 Investigational New Drug Applications (INDs)
21 CFR 314.126 Adequate and Well-Controlled Studies
21 CFR 610 General Biological Product Standards
21 CFR 610.12 Sterility Testing
21 CFR 610.13 Purity Testing
USP 24-(85) Bacterial Endotoxin Test
USP 24-(1510) Pyrogen Test
USP 24-(1171) Sterility

Main Article

Page created: August 06, 2012
Page updated: August 06, 2012
Page reviewed: August 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external